Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor

Pediatric Nephrology

Volumn 18, Issue 10, 2003, Pages 1073-1076

  Pattaragarn, Anirut ^a   Alon, Uri S ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b NONE   (United States)

Author keywords

Amiloride; Cyclooxygenase; Hydrochlorothiazide; Indomethacin; Nephrogenic diabetes insipidus; Rofecoxib; Tolmetin

Indexed keywords

AMILORIDE; CYCLOOXYGENASE 2 INHIBITOR; HYDROCHLOROTHIAZIDE; INDOMETACIN; ROFECOXIB; TOLMETIN; VASOPRESSIN;

ARTICLE; ARTIFICIAL MILK; CASE REPORT; CHILD DEVELOPMENT; CHILD GROWTH; DEHYDRATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG RESPONSE; ECHOGRAPHY; FAILURE TO THRIVE; FAMILY HISTORY; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPONATREMIA; MALE; NEPHROGENIC DIABETES INSIPIDUS; NEWBORN; POLYURIA; PRIORITY JOURNAL; SODIUM RESTRICTION; URINARY TRACT; URINE VOLUME; WATER LOSS;

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIABETES INSIPIDUS, NEPHROGENIC; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; INFANT, NEWBORN; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SODIUM CHLORIDE SYMPORTER INHIBITORS; SULFONES;

EID: 0141954946     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-003-1195-0     Document Type: Article

References (28)

1. Lieburg AF van, Knoers NV, Monnens LA (1999) Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 10:1958-1964
2. Alon U, Chan JC (1985) Hydrochlorothiazide-amiloride in the treatment of congenital nephrogenic diabetes insipidus. Am J Nephrol 5:9-13
3. Knoers N, Monnens LA (1990) Amiloride-hydrochlorothiazide versus indomethacin-hydrochlorothiazide in the treatment of nephrogenic diabetes insipidus. J Pediatr 117:499-502
4. Knoers NV, Monnens LA (1999) Nephrogenic diabetes insipidus. In: Barratt TM, Avner ED, Harmon WE (eds) Pediatric nephrology. Lippincott Williams and Wilkins, Baltimore, pp 583-591
5. Insel PA (1995) Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Gilman AG, Limbird LE (eds) Goodman and Gilman's the pharmacological basis of therapeutics. McGraw-Hill, Columbus, pp 617-657
6. Knoers NV, Deen PM (2001) Molecular and cellular defects in nephrogenic diabetes insipidus. Pediatr Nephrol 16:1146-1152
7. Ouweland AM van den, Knoop MT, Knoers VV, Markslag PW, Rocchi M, Warren ST, Ropers HH, Fahrenholz F, Monnens LA, Oost BA van (1992) Colocalization of the gene for nephrogenic diabetes insipidus (DIR) and the vasopressin type 2 receptor gene (AVPR2) in the Xq28 region. Genomics 13:1350-1352
8. Deen PM, Verdijk MA, Knoers NV, Wieringa B, Monnens LA, Os CH van, Oost BA van (1994) Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 264:92-95
9. Hoekstra JA, Lieburg AF van, Monnens LA, Hulstijn-Dirkmaat GM, Knoers VV (1996) Cognitive and psychosocial functioning of patients with congenital nephrogenic diabetes insipidus. Am J Med Genet 61:81-88
10. Blachar Y, Zadik Z, Shemesh M, Kaplan BS, Levin S (1980) The effect of inhibition of prostaglandin synthesis on free water and osmolar clearances in patients with hereditary nephrogenic diabetes insipidus. Int J Pediatr Nephrol 1:48-52
11. Chevalier RL, Rogol AD (1982) Tolmetin sodium in the management of nephrogenic diabetes insipidus. J Pediatr 101:787-789
12. Alon U, Wellons MD, Chan JC (1985) Hydrochlorothiazide, amiloride and tolmetin in the treatment of diabetes insipidus of Brattleboro rats. Med Biol 63:117-122
13. Jakobsson B, Berg U (1994) Effect of hydrochlorothiazide and indomethacin treatment on renal function in nephrogenic diabetes insipidus. Acta Paediatr 83:522-525
14. Earley LE, Orloff J (1962) The mechanism of antidiuresis associated with vasopressin-resistant diabetes insipidus. J Clin Invest 41:1988-1997
15. Magaldi AJ (2000) New insights into the paradoxical effect of thiazides in diabetes insipidus therapy. Nephrol Dial Transplant 15:1903-1905
16. Khan KN, Venturini CM, Bunch RT, Brassard JA, Koki AT, Morris DL, Trump BF, Maziasz TJ, Alden CL (1998) Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol 26:612-620
17. Harris RC Jr (2002) Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 89:10D-17D
18. Walker LA, Whorton AR, Smigel M, France R, Frolich JC (1978) Antidiuretic hormone increases renal prostaglandin synthesis in vivo. Am J Physiol 235:F180-185
19. Haas JA, Knox FG (1996) Effect of meclofenamate or ketoconazole on the natriuretic response to increased pressure. J Lab Clin Med 128:202-207
20. Gross JM, Dwyer JE, Knox FG (1999) Natriuretic response to increased pressure is preserved with COX-2 inhibitors. Hypertension 34:1163-1167
21. Brater DC (1999) Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 107:65S-70S; discussion 70S-71S
22. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M (1999) Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66:76-84
23. Matheson AJ, Figgitt DP (2001). Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs 61:833-865
24. Reinalter SC, Jeck,N, Brochhausen C, Koemhoff M, Seyberth HW (2002) Selective inhibition of cyclooxygenase-2 in patients with congenital salt-losing tubulopathies with antenatal onset. Pediatr Res 51:423A
25. Graham GG, Graham RI, Day RO (2002) Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). Curr Pharm Des 8:1063-1075
26. Alper AB Jr, Meleg-Smith S, Krane NK (2002) Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis 40:1086-1090
27. Papaioannides D, Bouropoulos C, Sinapides D, Korantzopoulos P, Akritidis N (2001) Acute renal dysfunction associated with selective COX-2 inhibitor therapy. Int Urol Nephrol 33: 609-611
28. Giovanni G, Giovanni P (2002) Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects? J Nephrol 15:480-488